Pancreatic Metastases Originating from Intestinal Neuroendocrine Tumours Abstract #2733

Introduction: Pancreatic metastases are rare, accounting for 1 to 2% of pancreatic tumours. Data on pancreatic metastases of intestinal NETs are lacking.
Aim(s): Description of frequency and outcome of patients with pancreatic metastases of intestinal neuroendocrine tumours (NET).
Materials and methods: In 1998 we established a database for patients with NET at our hospital. We searched this clinical database for all patients with intestinal NET and pancreatic metastases (PM).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Anja Rinke

To read results and conclusion, please login ...

Further abstracts you may be interested in

#62 Genome-wide DNA methylation profiling of pancreatic neuroendocrine tumors identifies distinct methylation profiles and differentially methylated gene promoter regions associated with low, medium and high grade tumors
Introduction: Integration of genetics and epigenetics has emerged as a powerful approach to studying cellular differentiation (Mikkelsen et al, 2009) and tumorigenesis (Shen et al, 2007). The study of DNA methylation is of particular importance in cancer, as causal involvement has been demonstrated and it is the most stable of all epigenetic modifications, making it a desirable marker for both early detection and treatment of tumors. Hypermethylation of CpG sites in gene promoter regions leads to decreased gene expression; if such a gene is a tumor suppressor, this leads to carcinogenesis. To date, there have been no studies of genome-wide DNA methylation profiling of NETs. This study sets out to determine the DNA methylation profiles of low, intermediate and high grade pancreatic NET liver metastases with the intention of identifying dysregulated biological pathways in the development of these tumors. A protocol for the analysis formalin-fixed paraffin embedded tissue (FFPE) has also been developed in order to study these tumors in significant numbers following this pilot study.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Christina Thirlwell
#81 Gastroenteropancreatic neuroendocrine tumors (GEP-NETs): our experience in a multidisciplinary team in a university hospital
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have a low incidence and prevalence representing < 2% of all gastrointestinal tumors with a heterogeneous biological behavior and an often complex management.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Jose Manuel Cabezas-Agricola
#91 Endoscopic ultrasound of 66 insulinomas
Introduction: Ultrasound is the virtual representation of the morphology of organs and tissues. Endoscopic ultrasound can be used in detailed scanning of pancreas and preoperative topical diagnostics of insulinomas. Insulinoma requires surgical treatment in all cases. This fact allows control of preoperative diagnostic methods.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Tatiana L. Silina
#97 The role of Ki-67 in the prognosis and management of neuroendocrine (NET) patients in a multdisciplinary cancer center
Introduction: The role of Ki-67 in NETs has become increasingly important, especially in light of the current trend in oncology to incorporate pathological molecular characteristics in determining treatment. In North America, Ki-67 is used inconsistently, as there exists some debate in the literature about its predictive value.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Simron Singh
Authors: Singh S, Rowsel C, Ingber N, Yang S, ...
#126 Assessment of the proliferation marker Ki-67 by endoscopic ultrasound guided-Fine Needle Aspiration (EUS-FNA) in pancreatic endocrine tumors: A comparative analysis with histology of the surgical specimen
Introduction: Assessment of the proliferative index by Ki-67 immuno-labelling is an important prognostic parameter for the biologic behavior of digestive neuroendocrine tumors, usually established on the histological specimen obtained after surgery or macro-biopsy. However, small pancreatic endocrine tumors (PET) are more and more often recognized by CT/MRI and diagnosed by EUS. The value of Ki-67 labelling index (Ki-67-LI) on fine needle aspiration (FNA) is not well-established in this setting, although regularly assessed.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Ivan Borbath